{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS (2026Q2)",
      "prediction": "BEAT",
      "answer": "pred ~$2.10 vs. cons $2.07",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic net revenue growth (2026Q2)",
      "prediction": "BEAT",
      "answer": "pred ~5.4% vs. cons 5.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Smoke-free organic net revenue growth (2026Q2)",
      "prediction": "IN-LINE",
      "answer": "pred ~10.2% vs. cons 10.3%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted diluted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$8.39 vs. cons $8.43 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic net revenue growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~6.0% vs. cons 6.0% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic operating income growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~8.0% vs. cons 8.0% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.6,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "An EPS beat of ~$2.10 vs. $2.07 consensus paired with an unchanged FY2026 midpoint of ~$8.39 vs. $8.43 consensus implies roughly $4.33 of second-half EPS versus approximately $4.40 embedded in consensus. That out-period shortfall should drive modest estimate cuts after the initial report, particularly given PM's premium valuation and continued uncertainty around U.S. ZYN growth and promotional spending.",
  "day5_confidence": "MEDIUM"
}